New York’s Cannabis Control Board (the “Board”) held its first public meeting today, kicking off a series of public meetings that will begin setting the regulations and guidelines for the adult-use cannabis market in New York. Led by Board Chair Tremaine Wright, the meeting was largely administrative. Some notable announcements from the meeting:
On October 1, 2021, the Department of Consumer Protection (the “Department”) published policies and procedures pertaining to the regulation of Adult-Use Cannabis (the “Regulations”) in accordance with Public Act 21-1. The Regulations outline the operational requirements and restrictions for the Adult-Use program, including the parameters by which individuals and businesses licensed by the Department will operate. The Regulations also set forth policies regarding consumer protections including product quality,… More
The Cannabis Control Commission announced in an August bulletin that it will begin reviewing all Marijuana Research Facility license applications previously submitted to the Commission.
A Research Facility license allows licensees to research cannabis and cannabis products for a variety of purposes, including under certain circumstances, studies involving human subjects. Research Facility licenses can be held by any number of different entities, including academic institutions, non-profits,… More
As was discussed in detail during Foley Hoag’s recent New Jersey webinar, the adult-use regulations released by the New Jersey Cannabis Regulatory Commission (“CRC”) contain several unanswered questions. For instance, when will the CRC begin accepting applications (they have already missed the statutory deadline)? How will applicants navigate the complexity of the local municipal approval process amidst towns seesawing between opt-ins and opt-outs?… More
The Food and Drug Administration (FDA) issued a consumer alert related to Delta-8 tetrahydrocannabinol (Delta-8 THC), following a recent increase in adverse event reports to FDA and poison control centers. Although Delta-8 THC products have proliferated in the market, FDA has not approved or evaluated any products containing the psychoactive cannabinoid and FDA is concerned that these products are being marketed in a manner that puts the public health at risk.… More
New Jersey has finally released its adult-use regulations outlining the manner in which licenses will be solicited, applications scored, and ultimately awarded. With a statutory deadline for the Cannabis Regulatory Commission to begin accepting applications within the next three weeks, preparation is sure to be a sprint. Foley Hoag’s application writing team has written and prepared several winning applications in multiple states, including New Jersey and recently Georgia.
Exactly five months after the passage of the Marijuana Regulation and Taxation Act (MRTA), on Tuesday, August 31st, New York Governor Kathy Hochul announced that she is convening an Extraordinary Session of the Legislature to announce her nominees to head the Office of Cannabis Management and the Cannabis Control Board (CCB), which governs the Office of Cannabis Management (OCM).
The OCM is the agency that will regulate cannabis and will issue licenses and develop regulations outlining how and when businesses can participate in the new industry.… More
The hemp cannabinoid marketplace has spent the last few years evolving at a fevered pace. However, for the first time in several years, we’re beginning to see a more mature marketplace, market participants, and most importantly, consumers. The market is now engaging in a renewed focus on scaling towards stricter best practices and regulatory frameworks. Please join us as we discuss not only where the marketplace is, but more so,… More
The New Jersey Cannabis Regulatory Commission (“CRC”) – ahead of schedule – just released its adult-use regulations, thereby taking the first step towards opening up its adult-use marketplace. While there is a tremendous amount of information to digest in the 160 pages of regulations, and the myriad implications and questions flowing from it, our cannabis team wanted to provide a brief overview of the relevant implications.
In short,… More
More than two years have passed since hemp-derived cannabidiol (CBD) was legalized in the United States under the Agriculture Improvement Act of 2018 (also known as the “Farm Bill”).
The Food and Drug Administration (FDA) has been exploring potential regulatory pathways for CBD but it has yet to engage in rulemaking or issue guidance that would provide a clear framework under which FDA could maintain oversight over CBD to ensure that its use in a range of products is safe.… More